Navigation Links
New Study Shows Doxorubicin Plus Paclitaxel Followed by Weekly,Paclitaxel as Adjuvant Therapy for High Risk Breast Cancer,Warranted in Place of Doxorubicin Plus Cyclophosphamide Followed by,Paclitaxel

Hoverman, M.D., Medical Director of Managed Care, US Oncology: Assessment of medication safety in the outpatient setting -- Manuel Modiano, M.D.: A phase I study of TPI 287, a third generation taxane, administered every 21 days in patients with advanced cancer -- Joanne Blum, M.D., Ph.D.: Phase II study of eribulin mesylate (E7389) halichondrin b analog in patients with refractory breast cancer -- Alexander Spira, M.D.: Phase II study of eribulin mesylate (E7389), a mechanistically novel inhibitor of microtubule dynamics, in patients with advanced Non-Small Cell-Lung Cancer (NSCLC) -- John Pippen, Jr., M.D., F.A.C.P.: "A Historical Overview of the Treatment of Prostate Cancer and the Evolution of Bone Marrow Transplantation" -- Marcus Neubauer, M.D., Co-Chair: Lung Cancer Research Committee: A clinical pathways project to promote evidence-based medicine in a large community oncology practice -- Domingo Perez, M.D.: Phase II trial of carboplatin, weekly paclitaxel and biweekly bevacizumab in patients with unresectable stage IV melanoma -- Nicholas Robert, M.D., Co-Chair Breast Cancer Research Committee: BCIRG 006: Docetaxel and trastuzumab-based regimens improve DFS and OS over AC-T in node positive and high risk node negative HER2 positive early breast cancer patients: Quality of Life (QOL) at 36 months follow-up -- Dr. Alexander Spira: Perifosine (P) an active agent in the treatment of patients with advanced sarcoma -- Dr. Alexander Spira: iTARGET: A Phase II Trial to Assess the Response to Gefitinib in Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell-Lung Cancer (NSCLC) Tumors -- Dr. Hakan Kaya: Survival outcomes for multiple myeloma over three decades: A Surveillance, Epidemiology, and End Results (SEER) analysis -- Dr. Hakan Kaya:
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
Post Your Comments:
(Date:5/1/2015)... 2015   Heska Corporation (NASDAQ: HSKA ... of advanced veterinary diagnostic and other specialty veterinary products ... will present at the 16th Annual B. Riley & Co. ... The conference will be held May 12-14, 2015 at Lowes ... management will be available during the day on May 13 ...
(Date:5/1/2015)... 1, 2015 Braeburn Pharmaceuticals announced ... therapeutic focus beyond addiction and pain to ... Braeburn has acquired an implantable, six-month formulation ... for treatment of schizophrenia from Endo Pharmaceuticals. ... rights to other potential applications of the ...
(Date:5/1/2015)... , May 1, 2015  Boston Scientific Corporation (NYSE: ... continued business momentum and long-term growth strategies at a ... New York City . President and Chief Executive ... opportunities the company has to bring forward meaningful innovation ... markets and deliver shareholder value. "We ...
Breaking Medicine Technology:Heska to Present at the 16th Annual B. Riley & Co. Investor Conference 2Braeburn Pharmaceuticals expands pipeline to include two schizophrenia treatments 2Braeburn Pharmaceuticals expands pipeline to include two schizophrenia treatments 3Braeburn Pharmaceuticals expands pipeline to include two schizophrenia treatments 4Boston Scientific Outlines Growth And Expansion Strategy At 2015 Investor Day 2Boston Scientific Outlines Growth And Expansion Strategy At 2015 Investor Day 3Boston Scientific Outlines Growth And Expansion Strategy At 2015 Investor Day 4Boston Scientific Outlines Growth And Expansion Strategy At 2015 Investor Day 5Boston Scientific Outlines Growth And Expansion Strategy At 2015 Investor Day 6Boston Scientific Outlines Growth And Expansion Strategy At 2015 Investor Day 7
... 2011 The oncology market continues to be a ... all the aspects of successfully launching a new oncology ... supporting the oncology therapeutic area are constantly assessing the ... group. Best Practices, LLC, a leader in ...
... MUNDELEIN, Ill., April 19, 2011 Sysmex, a ... information systems technology, announced today an amended distributorship ... which automatically renews for up to four successive ... instruments including the Sysmex pocH-100 i™ , Sysmex ...
Cached Medicine Technology:Oncology Global Strategic Marketing Study Offers Chance for Resource Benchmarks 2Sysmex America Signs Distributorship Agreement With LABSCO 2
(Date:5/2/2015)... As a nonsurgical staple in the ... neck and décolleté, radiofrequency energy is proving to ... the success of vulvovaginal rejuvenation. In a pilot ... ThermiGyn’s Women’s Health Clinical Advisory Board Chairman Red ... temperature controlled radio frequency, specifically that of ThermiVa, ...
(Date:5/1/2015)... Texas (PRWEB) May 02, 2015 IDLife ... Texas, is proud to announce the addition of its ... Widerstrom is a life long athlete, growing up in ... passion after college by becoming a personal trainer and ... been the face of several TV shows highlighting her ...
(Date:5/1/2015)... (PRWEB) May 01, 2015 Jusuru International ... for the successful repositioning of its flagship nutritional supplement, ... brand with a new name, new logo, new packaging, ... Ethos Awards are designed to identify and promote programs ... best. , “DSA congratulates Jusuru International for their ...
(Date:5/1/2015)... 01, 2015 TROY Healthcare Solutions is ... Regional User Group (RUG) Conference in Atlanta, GA from ... User Group Conference provides a forum for client-to-client presentations, ... all aspects of electronic medical record operations, as well ... applications. , In addition to sponsoring the event, TROY ...
(Date:5/1/2015)... Ernst & Young (EY) has announced Melanie ... CSO, and Burak Sezen, Co-Founder & CTO of RowdMap, ... Of The Year® 2015 Awards in the Ohio Valley ... global leader in assurance, tax, transaction and advisory services ... top audit companies in the world. The awards program ...
Breaking Medicine News(10 mins):Health News:Study Demonstrates Efficacy of Temperature Controlled Radiofrequency for Vulvovaginal Laxity 2Health News:Study Demonstrates Efficacy of Temperature Controlled Radiofrequency for Vulvovaginal Laxity 3Health News:IDLife LLC Announces New Partnership with Fitness Celebrity, Jen Widerstrom 2Health News:Jusuru International Receives 2015 DSA Ethos Award 2Health News:Jusuru International Receives 2015 DSA Ethos Award 3Health News:Jusuru International Receives 2015 DSA Ethos Award 4Health News:Jusuru International Receives 2015 DSA Ethos Award 5Health News:TROY Healthcare to Exhibit at the Cerner Southeast Regional User Group Conference 2Health News:TROY Healthcare to Exhibit at the Cerner Southeast Regional User Group Conference 3Health News:RowdMap, Inc. Named as a Ernst & Young Entrepreneur Of The Year® 2015 Award Finalist 2
... one of the leading publishers in the fields of ... The Endocrine Society to co-publish a new journal, ... Hormonal cancers include two of the most deadly cancer ... addition to these cancers, Hormones & Cancer ...
... , CHICAGO, Aug. 27 For years, it was ... procedures to save teeth compromised by extensive decay, gum disease and ... said times have changed and patients should forego prolonged dental heroics ... , , "There really is no justification ...
... ... at ASHG 2009 Meeting in Honolulu, Hawaii -- October 20-24, 2009, Hawaii Convention Center ... Bethesda, MD (Vocus) August 27, ... in Honolulu, Hawaii to present their latest research findings at the 59th Annual Meeting ...
... ... is trying to identify some of the factors that play into a smoker,s decision to quit. ... Manhasset, NY (Vocus) August 27, 2009 ... you may get an equal number of different answers. Christine Metz, PhD, is a scientist at ...
... shows , THURSDAY, Aug. 27 (HealthDay News) -- Children ... overcome their allergy by drinking increasingly higher doses of ... from Johns Hopkins Children,s Center in Baltimore reported that ... immune systems to tolerate milk and other dairy products ...
... , WEST PALM BEACH, Fla., Aug. ... is has added a new module designed to help physicians manage ... service and employee motivation are two of the most important yet ... Beer. , , Leading this new module is ...
Cached Medicine News:Health News:Springer signs publishing agreement with the Endocrine Society 2Health News:Why Save Bad Teeth? Dental 'Heroics' Unnecessary and Failure Prone 2Health News:The American Society of Human Genetics Hosts 59th Annual Meeting 2Health News:The American Society of Human Genetics Hosts 59th Annual Meeting 3Health News:The American Society of Human Genetics Hosts 59th Annual Meeting 4Health News:The American Society of Human Genetics Hosts 59th Annual Meeting 5Health News:Scientist at The Fienstein Instute for Medical Research Discovers Quitting Smoking Promotes Anti-Inflammatory Response 2Health News:Scientist at The Fienstein Instute for Medical Research Discovers Quitting Smoking Promotes Anti-Inflammatory Response 3Health News:Milk Allergy Symptoms May Ease With Exposure 2
Inquire...
Integrated closure system provides security you can feel as the plastic fasteners lock into place and is both easy to close, empty and clean....
Flextend is a hydrocolloid skin barrier that is designed to be the most resistant to discharge and is the barrier of choice for urostomies and high output ileosotomies....
Inquire...
Medicine Products: